GALNS Data Overshadowed
Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline. (BioWorld Today)